Jennings, M. T. and J. A. Pietenpol ( 1998). "The role of transforming growth factor beta in glioma progression." J Neurooncol 36(2): 123-40. Protocol # CL-PTL 105 CONFIDENTIAL AM #9 09/25/15 Page 84 89. Kasid, A., G. I. Bell, et al. (1988). "Effects of transfo rming growth factor-beta on human lymphokine-activated kille r cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells." J Immunol 141(2): 690-8. 90. Kaufman, H. L., W. W ang, et al. (2004). "Phase II randomized study of vaccine treatment of advanced prostate canc er (E7897): a trial of the Eastern Cooperative Oncology Group." J Clin Oncol 22(11): 2122-32. 91. Kawano, T., J. Cui, et al. (1997). " CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides." Science 278(5343): 1626-9. 92. Keilholz, U., J. Weber, et al. (2002). "Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy." J Immunother 25(2): 97-138. 93. Kim, S. J., Y. H. Im, et al. (2000). "M olecular mechanisms of inactivation of TGF- beta receptors during carcinogenesis ." Cytokine Growth Factor Rev 11(1-2): 159- 68. 94. Klein, L., L. Trautman, et al. (2003). "Visualizing the course of antigen-specific CD8 and CD4 T cell responses to a growing tumor." Eur J Immunol 33(3): 806- 14. 95. Knuth, A., T. Wolfel, et al. (1989). "Cytolytic T-cell clones against an autologous human melanoma: specific ity study and definition of three antigens by immunoselection." Proc Natl Acad Sci U S A 86(8): 2804-8. 96. Kong, F. M., M. S. Anscher, et al. (1995). "Elevated plasma transforming growth factor-beta 1 levels in br east cancer patients decrease after surgical removal of the tumor." Ann Surg 222(2): 155-62. 97.